Baqsimi Powder
Product Images NDC 0548-8351

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Baqsimi (NDC 0548-8351). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amphastar Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Baqsimi 3 mg nasal powder packaging label showing the box design for glucagon nasal powder. The label highlights the product name, strength, nasal use route, and treatment indication for severe low blood sugar. It includes usage instructions, regulatory and barcode information, and the Amphastar Pharmaceuticals, Inc. labeler logo.*

FDA Label Image

Carton 2 (Carton2)

Baqsimi 3 mg nasal powder packaging label from Amphastar Pharmaceuticals, Inc. The label indicates it contains glucagon nasal powder for treatment of severe low blood sugar. The box includes two nasal devices and instructions for nasal use only. The packaging emphasizes the product is prescription only and instructs users to keep tubes sealed until ready to use.*

FDA Label Image

Figure1 (Figure1)

A line graph illustrating the change in mean glucose levels (mg/dL) over time (minutes) for 3-mg Baqsimi nasal powder. The graph shows glucose levels rising from about 54 mg/dL at 0 minutes to approximately 190 mg/dL by 80 minutes, with time on the x-axis and mean glucose on the y-axis.*

FDA Label Image

Figure2 (Figure2)

A line graph showing mean glucose levels (mg/dL) over time (minutes) for three pediatric age groups: 4 to under 8 years, 8 to under 12 years, and 12 to under 17 years. Glucose increases from about 70 mg/dL at 0 minutes to peaks between 180-200 mg/dL around 60 minutes, then slightly declines by 90 minutes.*

FDA Label Image

Ifu1 (Ifu1)

An instructional diagram showing the labeled parts of a Baqsimi nasal powder device. The parts identified include the Tube, Lid, Tip, Device, Plunger, and a Green Line on the device. This illustration provides a visual guide to the components of the Baqsimi 3 mg nasal powder delivery system by Amphastar Pharmaceuticals, Inc.*

FDA Label Image

Ifu2 (Ifu2)

An illustration showing a yellow-and-white container with a red shrink wrap seal at the top. The image highlights the shrink wrap section, likely indicating part of the packaging or safety feature for the product Baqsimi nasal powder by Amphastar Pharmaceuticals.*

FDA Label Image

Ifu3 (Ifu3)

An instructional illustration showing hands holding a Baqsimi nasal powder delivery device. The diagram labels the parts: a yellow tube, a lid, and the nasal device, demonstrating how to assemble or handle the components.*

FDA Label Image

Ifu4 (Ifu4)

An instructional diagram showing a hand holding a nasal powder delivery device. It points out key parts labeled as Tip, Plunger, and a Green line on the plunger, indicating correct positioning or usage step for Baqsimi nasal powder (glucagon).*

FDA Label Image

Ifu5 (Ifu5)

An instructional illustration showing a hand holding a Baqsimi nasal powder drug delivery device near a nose, demonstrating its use by positioning the device at the nostril for nasal administration.*

FDA Label Image

Ifu6 (Ifu6)

An instructional illustration showing a hand holding a nasal spray device labeled as step 3 in a sequence. The device is positioned near a nostril, with small dots representing a spray being administered into the nose.*

FDA Label Image

Ifu7 (Ifu7)

The image shows a portion of the Baqsimi 3 mg nasal powder packaging by Amphastar Pharmaceuticals, Inc. It displays the side of the box highlighting the designated Expiration Date area in black, located near the top edge. The packaging features a yellow and white color scheme with a red-capped nasal applicator partially visible.*

FDA Label Image

Structure (Structure)

Chemical structure of glucagon represented as a linear peptide chain with amino acid residues labeled from position 1 to 29, beginning with histidine (His) at the N-terminus and ending with threonine (Thr) at the C-terminus.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.